본문바로가기
Q
U
I
C
K

PR

SK bioscience company news updates

Press releases

SK biosciences Underwriters for IPO Promotion

2020. 07. 26

- NH Investment & Securities wereed as the lead underwriter and Korea Investment & Securities as the co-underwriter for SK bioscience’s IPO.
- SK bioscience plans to be listed for the next year to expand business and accelerate growth by securing new investment


SK바이오사이언스 로고


SK bioscience announced that the company hased the NH Investment & Securities as a lead underwriter and Korea Investment & Securities as its co-underwriter to manage an initial public offering (IPO) for 2021.

SK bioscience plans to expand its business and accelerate further growth by securing new investment.

SK bioscience has developed SKYCellflu® Quadrivalent, the world´s first cell culture-based quadrivalent influenza vaccine, SKYZoster®, the world´s second shingles vaccine, and SKYVaricella®, the second varicella vaccine developed in Korea. New products currently being developed include a COVID-19 vaccine and a next-generation pneumococcal vaccine.

SK bioscience has been actively advancing to overseas markets and expanding its business portfolio. The company recently signed a CMO contract with AstraZeneca, a global pharmaceutical company, to supply COVID 19 vaccines in Korea and abroad.

A company official said, "The IPO will be conducted under proper evaluation.”